arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

STANDARD BIOTOOLS INC.

LAB
$0.74 ▼ -0.01 (-1.52%) at close
Industrials ·Laboratory Analytical Instruments ·USLaboratory Analytical Instruments
68 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
19
Health
Poor
Bearish
auto_awesome

Analytical Summary

STANDARD BIOTOOLS INC. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $289.3M
Dividend Yield
Revenue Growth -7.6%
Op. Margin -126.3%
ROIC -4.7%
FCF / Share $-0.03
Trailing P/E
Price / Book 0.5x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

68-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$20.10M
↓ -7.6%
Net Income Profit after all expenses
$127.07M
— 0.0%
Operating Margin Operating profit as % of sales
-126.3%
↓ -113.7% 1th
FCF / Share Free cash flow per share
$-0.03
↑ +77.6%
Long-Term Debt Long-term obligations
$55.21M
— +0.2%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
2
Returns
29
Financial Health
1
Cash Quality
70

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 18 years · 68 quarters